Study to Determine the Intra-subject Variability of Pharmacokinetics of Lomitapide in Healthy Subjects

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-07-29

Study Completion Date

2013-08-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Objectives:

To evaluate the intra-subject variability of the pharmacokinetics (PK) of single oral capsule doses of 20 mg lomitapide.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacokinetic Single Dose Study of Oral Lasmiditan in Participants With Normal and Impaired Hepatic Function

NCT03040479

Migraine

COMPLETED PHASE1

Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function

NCT04116476

Mild and Moderate Hepatic Impairment

COMPLETED PHASE1

A Study to Compare a Single-dose of Two Different Formulations of ACT-709478 in Healthy Men

NCT04123288

Healthy Subjects

COMPLETED PHASE1

Study Evaluating the Pharmacokinetics of the Potential Drug Interaction Between CYP2C9 Inhibitor and Substrate

NCT00369304

Healthy Subjects

COMPLETED PHASE1

A Biopharmaceutics Study to Assess the Pharmacokinetics of Single Oral and IV Doses of Olorofim

NCT04207957

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will be a single centre, open-label study. It will comprise of 2 single oral doses with at least a 14-day washout between doses. Following the first dose subjects will be discharged from the unit for the remainder of the washout period. Subjects will be re-admitted to the unit on Day -1 (Period 2) and following an overnight fast they will be administered the second dose on Day 1 (Period 2). Subjects will be discharged from the unit following the 168 h PK blood draw.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intra-subject Variability of Pharmacokinetics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

lomitapide

It will comprise of 2 single oral doses with at least a 14-day washout between doses.

Group Type EXPERIMENTAL

lomitapide

Intervention Type DRUG

20 mg dose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

lomitapide

20 mg dose

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Juxtapid

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is a non-smoking healthy male or female, aged between 18 and 40 years of age.
2. Subject has a BMI of 18.5 - 25 kg/m2.
3. Subject has total body weight between \> 50 kg to ≤ 100 kg.
4. Subjects must agree to use acceptable methods of contraception.
5. All females, regardless of childbearing potential, must have a negative serum beta human chorionic gonadotropin pregnancy test at Screening and on admission.
6. In good health, determined by no clinically significant or relevant abnormalities identified by a detailed medical history \& full physical examination.
7. No known history of hypersensitivity or previous intolerance to lomitapide.
8. Subjects must be capable of understanding and complying with the requirements of the protocol and must have signed the informed consent form prior to undergoing any study-related procedures.

Exclusion Criteria

1. Subject has a clinically significant disease or any condition or disease that might affect drug absorption, distribution or excretion.
2. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs.
3. Any clinically significant abnormal laboratory, vital signs or other safety findings as determined by medical history, physical examination or other evaluations.
4. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator;
5. Electrocardiogram (ECG) abnormalities in the standard 12-lead ECG (at screening) such as a QTcF interval of \>450 msec, a history of a prolonged QTc interval or Brugada syndrome.
6. History or current evidence of any clinically relevant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrinological, allergic, dermatological, metabolic, neurological, psychiatric or other disease.
7. History or laboratory evidence of Gilbert's syndrome.
8. Positive results in any of the serology tests for Hepatitis B Surface Antigen (HbsAg), anti-Hepatitis core antibody (anti-HBc Ig G \[and anti-HBc IgM if IgG is positive\], Hepatitis C antibodies (anti-HCV), and HIV 1 and 2 antibodies, (anti-HIV 1/2).
9. Use of any drugs of abuse within 6 months prior to admission.
10. Confirmed positive results from urine drug screen (amphetamines, benzodiazepines, cocaine, cannabinoids, opiates, barbiturates and methadone) or from the alcohol breath test at screening and on admission (Day -1).
11. History or clinical evidence of alcohol or drug abuse within one year prior to admission.
12. Mentally handicapped.
13. Participation in a drug trial within 90 days prior to first drug administration.
14. Use of any prescription medication within 2 weeks prior to admission (Day -1), with the exception of the oral contraceptive pill.
15. Use of any substance inducing or inhibiting CYP3A4 enzymes within 30 days prior to admission (Day -1).
16. Use of any over-the-counter (OTC) medication (including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations) within 7 days prior to admission (Day -1), unless deemed acceptable by the Investigator and Sponsor.
17. Use of alcohol-, grapefruit-, starfruit-, or caffeine-containing foods or beverages within 72 hours prior to admission and through Study Completion.
18. Donation of more than 500 mL of blood within 90 days prior to drug administration.
19. Receipt of blood products within 2 months prior to admission.
20. Poor peripheral venous access.
21. Use of any tobacco- or nicotine-containing products within 6 months prior to admission (Day -1).
22. Any acute or chronic condition, scheduled hospitalisation (inclusive of elective surgery during study), or scheduled travel prior to completion of all study procedures.
23. Any circumstances or conditions, which, in the opinion of the PI, may affect full participation in the trial or compliance with the protocol.
24. Legal incapacity or limited legal capacity at screening.
25. Subjects who are vegetarians, vegans or have any dietary restrictions conflicting with the study standardised menus.

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes